|
|
|
|
FDA imposes new safety requirements to curb use of LABAs in asthma patients
This decision was based upon an analysis of data from a surveillance study (Salmeterol Nationwide Surveillance Study; SNS), a large, randomized trial (Salmeterol Multicenter Asthma Research Trial; SMART), and a meta-analysis of asthma patients.Data from the...
|
|
|
FDA imposes new safety requirements to curb use of LABAs in asthma patients
This decision was based upon an analysis of data from a surveillance study (Salmeterol Nationwide Surveillance Study; SNS), a large, randomized trial (Salmeterol Multicenter Asthma Research Trial; SMART), and a meta-analysis of asthma patients.Data from the...
|
|
|
FDA curbs LABA use for asthma
On February 18, FDA recommended drastic changes limiting the way long-acting beta2-adrenergic agonists (LABAs) are used to treat asthma.This decision was based upon an analysis of data from a surveillance study (Salmeterol Nationwide Surveillance Study; SNS)...
|
|
|
Claims Pared In Dey, Sepracor IP Fight Over Brovana
Sepracor Inc.and Dey LP have agreed to dismiss a range of individual patent claims in their battle over Sepracor's rollout of chronic obstructive pulmonary disease drug Brovana. Claims Pared In Dey, Sepracor IP Fight Over Brovana.
|
|
|
FDA curbs LABA use for asthma
On February 18, FDA recommended drastic changes limiting the way long-acting beta2-adrenergic agonists (LABAs) are used to treat asthma.This decision was based upon an analysis of data from a surveillance study (Salmeterol Nationwide Surveillance Study; SNS)...
|
|
|
FDA Says LABA Asthma Drugs Not for Solo Use
Long-acting beta agonist (LABA) agents should never be used alone in children or adults with asthma, the FDA said today in announcing label changes and other initiatives intended to promote safe use of these popular drugs.Package inserts for the two single...
|
